DISAPPEARANCE OF AML1-MTG8(ETO) FUSION TRANSCRIPT IN ACUTE MYELOID-LEUKEMIA PATIENTS WITH T(8-21) IN LONG-TERM REMISSION

被引:59
作者
SATAKE, N
MASEKI, N
KOZU, T
SAKASHITA, A
KOBAYASHI, H
SAKURAI, M
OHKI, M
KANEKO, Y
机构
[1] SAITAMA CANC CTR HOSP, DEPT CANC CHEMOTHERAPY, INA, SAITAMA 362, JAPAN
[2] SAITAMA CANC CTR HOSP, DEPT CLIN 3, HAEMATOL CLIN, INA, SAITAMA 362, JAPAN
[3] SAITAMA CANC CTR, RES INST, DEPT VIROL & IMMUNOL, INA, SAITAMA 362, JAPAN
[4] NATL CANC CTR, RES INST, DIV RADIOBIOL, TOKYO 104, JAPAN
关键词
AML1-MTG8 FUSION TRANSCRIPT; T(8-21)-ASSOCIATED ACUTE MYELOID LEUKEMIA; LONG-TERM SURVIVOR; MINIMAL RESIDUAL DISEASE; REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION;
D O I
10.1111/j.1365-2141.1995.tb05406.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a study of 23 patients with t(8;21)-associated acute myeloid leukaemia the AML1-MTG8 fusion transcript was present in the majority of serial samples obtained from 17 patients followed for up to 34 months after diagnosis, but was absent in samples from an six patients who had been in continuous complete remission for 61 months after allogeneic bone marrow transplantation (BMT), or for 52, 53, 123, 182 and 198 months, respectively, after courses of intensive chemotherapy, Previous studies showed that the AML1-MTG8 fusion, transcript was present in most patients with this type of translocation in long-term remission, Our results indicate that blood cells of patients with t(8;21) in remission of over 10 years may not show the AML1-MTG8 fusion transcript, and that those of patients who have undergone allogeneic BMT or intensive chemotherapy may become fusion transcript-negative much earlier, Our study suggests that leukaemic cells with the AML1-MTG8 fusion transcript may survive for some time after courses of chemotherapy or BMT, but that they may eventually be eradicated by immunologic and other antileukaemic mechanisms.
引用
收藏
页码:892 / 898
页数:7
相关论文
共 28 条
[21]  
NUCIFORA G, 1993, BLOOD, V82, P712
[22]   DETECTION OF THE CHROMOSOME-16 CBF-BETA-MYH11 FUSION TRANSCRIPT IN MYELOMONOCYTIC LEUKEMIAS [J].
POIREL, H ;
RADFORDWEISS, I ;
RACK, K ;
TROUSSARD, X ;
VEIL, A ;
VALENSI, F ;
PICARD, F ;
GUESNU, M ;
LEBOEUF, D ;
MELLE, J ;
DREYFUS, F ;
FLANDRIN, G ;
MACINTYRE, E .
BLOOD, 1995, 85 (05) :1313-1322
[23]  
ROTH MS, 1992, BLOOD, V79, P276
[24]   FURTHER CHARACTERIZATION OF ACUTE MYELOGENOUS LEUKEMIA WITH T(8-21) CHROMOSOME-TRANSLOCATION [J].
SAKURAI, M ;
KANEKO, Y ;
ABE, R .
CANCER GENETICS AND CYTOGENETICS, 1982, 6 (02) :143-152
[25]   DETECTION OF T(8-21) BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION IN PATIENTS IN REMISSION OF ACUTE MYELOID-LEUKEMIA TYPE-M2 AFTER CHEMOTHERAPY OR BONE-MARROW TRANSPLANTATION [J].
SAUNDERS, MJ ;
TOBAL, K ;
YIN, JAL .
LEUKEMIA RESEARCH, 1994, 18 (12) :891-895
[26]  
TIGHE JE, 1993, BLOOD, V81, P592
[27]   ALTERNATIVE, OUT-OF-FRAME RUNT/MTG8 TRANSCRIPTS ARE ENCODED BY THE DERIVATIVE(8) CHROMOSOME IN THE T(821) OF ACUTE MYELOID-LEUKEMIA M2 [J].
TIGHE, JE ;
CALABI, F .
BLOOD, 1994, 84 (07) :2115-2121
[28]  
VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780